Pharmacogenomic insights into treatment and management of statin-induced myopathy
Open Access
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in Genome Medicine
- Vol. 1 (12) , 120
Abstract
Although statins are generally well tolerated, the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore, we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy, this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy.Keywords
This publication has 27 references indexed in Scilit:
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJACC, 2009
- Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathyThe Pharmacogenomics Journal, 2009
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- CYP2D6*4 polymorphism is associated with statin-induced muscle effectsPharmacogenetics and Genomics, 2007
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Suboptimal choices and dosing of statins at start of therapyBritish Journal of Clinical Pharmacology, 2005
- Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysisJournal of Clinical Pharmacy and Therapeutics, 2005
- A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatinJournal of Human Genetics, 2004
- ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of StatinsStroke, 2002